Antibody–drug conjugates have emerged as a powerful ... Protein degraders are a molecular class designed to transport a target protein to, and activate, native protein degradation machinery.

DB-1305/BNT325 was generally well tolerated and exhibited “very encouraging and durable antitumor activity in ovarian cancer patients,” said Maria Rubinstein, MD.

The FDA thinks an antibody-drug conjugate (ADC) developed by AbbVie could set new standards in treatment for certain patients with lung cancer, awarding the drug breakthrough status. Teliso-V ...

The only currently approved treatment for this patient population is the antibody-drug conjugate trastuzumab deruxtecan (T-DXd), which is delivered intravenously and has been linked to instances ...